Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial
Open Access
- 16 August 2019
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 35 (2) , 219-225
Abstract
In the absence of an intervening antiresorptive agent, cyclic administration of teriparatide does not increase bone mineral density (BMD) more than standard daily therapy. Because denosumab is a potent antiresorptive agent with a rapid off-effect, we hypothesized that it might be the optimal agent to help maximize bone gains with cyclic teriparatide. In this 3-year protocol, 70 postmenopausal women with osteoporosis were randomized to 18 months of teriparatide followed by 18 months of denosumab (standard) or three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab (cyclic). BMD (dual-energy X-ray absorptiometry [DXA]) measurements of lumbar spine (LS), total hip (TH), femoral neck (FN), and 1/3 radius (RAD) were performed every 6 months and total body bone mineral (TBBM) at 18 and 36 months. Baseline descriptive characteristics did not differ between groups except for a minimal difference in LS BMD but not T-score (mean age 65 years, mean LS T-score − 2.7). In the standard group, BMD increments at 36 months were: LS 16%, TH 4%, FN 3%, and TBBM 4.8% (all p < 0.001 versus baseline). In the cyclic group, 36-month BMD increments were similar: LS 12%, TH 4%, FN 4%, and TBBM 4.1% (all p < 0.001 versus baseline). At 36 months, the LS BMD increase with standard was slightly larger than with cyclic (p = 0.04), but at 18 months, in the cyclic group, there was no decline in RAD or TBBM (p = 0.007 and < 0.001, respectively, versus standard). Although the cyclic regimen did not improve BMD compared with standard at 36 months, there appeared to be a benefit at 18 months, especially in the highly cortical skeletal sites. This could be clinically relevant in patients at high imminent risk of fracture, particularly at nonvertebral sites. © 2019 American Society for Bone and Mineral Research. © 2019 American Society for Bone and Mineral Research.Keywords
Funding Information
- Amgen (Investigator Initiated Study)
- Eli Lilly and Company (provided study drug)
- F. Hoffmann-La Roche (provided reagents for biochemical marker assays)
- Amgen (Investigator Initiated Study)
- Eli Lilly and Company (provided study drug)
- F. Hoffmann-La Roche (provided reagents for biochemical marker assays)
This publication has 29 references indexed in Scilit:
- Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on AlendronateThe Journal of Clinical Endocrinology & Metabolism, 2015
- Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled TrialThe Journal of Clinical Endocrinology & Metabolism, 2014
- Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatmentBone, 2014
- Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosisJournal of Bone and Mineral Research, 2010
- Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosisOsteoporosis International, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Teriparatide Increases Bone Formation in Modeling and Remodeling Osteons and Enhances IGF-II Immunoreactivity in Postmenopausal Women With OsteoporosisJournal of Bone and Mineral Research, 2006
- Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy StudyJournal of Bone and Mineral Research, 2001
- Parathyroid Hormone Added to Established Hormone Therapy: Effects on Vertebral Fracture and Maintenance of Bone Mass After Parathyroid Hormone WithdrawalJournal of Bone and Mineral Research, 2001
- Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosisThe Lancet, 1997